HIK:LSEHikma Pharmaceuticals Plc Analysis
Data as of 2026-06-20 - not real-time
£1,457.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Hikma Pharmaceuticals trades at a **PE ratio of ~11**, well below the industry average of 24, and the DCF model suggests a fair value around £20.80, implying roughly **32% upside**. The company posted **8.5% revenue growth** YoY, maintains a **gross margin of 43.5%** and an **operating margin of 16.2%**, and its forward EPS of 1.85 points to continued earnings acceleration.
Technically, the stock sits just under its 20‑day SMA (1461) with a bearish MACD histogram and decreasing volume, indicating short‑term pressure, but a low **beta of 0.5** and modest 30‑day volatility (~19%) suggest limited downside risk. Recent news of the Supreme Court ending Amarin litigation removes a legal cloud, supporting a more stable outlook.
Technically, the stock sits just under its 20‑day SMA (1461) with a bearish MACD histogram and decreasing volume, indicating short‑term pressure, but a low **beta of 0.5** and modest 30‑day volatility (~19%) suggest limited downside risk. Recent news of the Supreme Court ending Amarin litigation removes a legal cloud, supporting a more stable outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram and price slightly below 20‑day SMA
- Decreasing volume trend reducing near‑term liquidity
- Support level at 1397 providing a floor for downside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap (PE ~11 vs industry ~24, 32% DCF upside)
- Stable earnings growth and improving forward EPS
- Low beta and moderate volatility limiting market risk
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent revenue growth and solid operating margins
- Diversified geographic footprint reducing concentration risk
- Resolution of Amarin patent litigation removing regulatory/legal uncertainty
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin12.00%
P/E Ratio10.8
ROE16.52%
ROA7.50%
Debt/Equity61.55
P/B Ratio1.7
Op. Cash Flow£436.0M
Free Cash Flow£-66125000
Industry P/E24.1
Technical Analysis
TrendNeutral
RSI52.6
Support£1,397.00
Resistance£1,503.00
MA 20£1,461.25
MA 50£1,420.92
MA 200£1,523.50
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Fair Value£2,080.35
Target Price£1,928.25
Upside/Downside32.34%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.50
Volatility19.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.